Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Chunyan Gu-Trantien, … , Christos Sotiriou, Karen Willard-Gallo
Chunyan Gu-Trantien, … , Christos Sotiriou, Karen Willard-Gallo
Published June 17, 2013
Citation Information: J Clin Invest. 2013;123(7):2873-2892. https://doi.org/10.1172/JCI67428.
View: Text | PDF
Research Article Oncology

CD4+ follicular helper T cell infiltration predicts breast cancer survival

  • Text
  • PDF
Abstract

CD4+ T cells are critical regulators of immune responses, but their functional role in human breast cancer is relatively unknown. The goal of this study was to produce an image of CD4+ T cells infiltrating breast tumors using limited ex vivo manipulation to better understand the in vivo differences associated with patient prognosis. We performed comprehensive molecular profiling of infiltrating CD4+ T cells isolated from untreated invasive primary tumors and found that the infiltrating T cell subpopulations included follicular helper T (Tfh) cells, which have not previously been found in solid tumors, as well as Th1, Th2, and Th17 effector memory cells and Tregs. T cell signaling pathway alterations included a mixture of activation and suppression characterized by restricted cytokine/chemokine production, which inversely paralleled lymphoid infiltration levels and could be reproduced in activated donor CD4+ T cells treated with primary tumor supernatant. A comparison of extensively versus minimally infiltrated tumors showed that CXCL13-producing CD4+ Tfh cells distinguish extensive immune infiltrates, principally located in tertiary lymphoid structure germinal centers. An 8-gene Tfh signature, signifying organized antitumor immunity, robustly predicted survival or preoperative response to chemotherapy. Our identification of CD4+ Tfh cells in breast cancer suggests that they are an important immune element whose presence in the tumor is a prognostic factor.

Authors

Chunyan Gu-Trantien, Sherene Loi, Soizic Garaud, Carole Equeter, Myriam Libin, Alexandre de Wind, Marie Ravoet, Hélène Le Buanec, Catherine Sibille, Germain Manfouo-Foutsop, Isabelle Veys, Benjamin Haibe-Kains, Sandeep K. Singhal, Stefan Michiels, Françoise Rothé, Roberto Salgado, Hugues Duvillier, Michail Ignatiadis, Christine Desmedt, Dominique Bron, Denis Larsimont, Martine Piccart, Christos Sotiriou, Karen Willard-Gallo

×

Figure 6

Tumor SN suppresses activation of donor CD4+ T cells.

Options: View larger image (or click on image) Download as PowerPoint
Tumor SN suppresses activation of donor CD4+ T cells.
 
D-PB CD4+ T cell...
D-PB CD4+ T cells (unstimulated or S) were treated for 24 hours with primary tumor SN. Expression of activation markers on (A) CD4+CD45RO+ T cells or (B) total CD4+ T cells. (C–I) TIL gene expression data (P1–P10) was compared with donor CD4+CD45RO+ T cells treated with SN with or without S (SN = 2 minimal [TIL034 and TIL043] and 2 extensive [TIL019 and TIL027; the latter is borderline extensive, Supplemental Table 1C] tumors; Supplemental Table 1C). Heat maps show genes commonly altered in TIL and donor cells treated with SN with or without S for the designated comparison (red, upregulated; blue, downregulated). Samples include TIL from minimally (P1, P3, P5, P6, P8, P9) and extensively (P2, P4, P7, P10) infiltrated tumors; SN-treated (n = 4), S-treated (n = 3), and SN+S-treated (n = 4) D-PB. Genes commonly altered in P1–P10 TIL versus their P-PB and (C) SN-treated, (D) SN+S-treated, or (E) S-treated donor cells are highlighted. (F) Genes differentially expressed in TIL from extensively versus minimally infiltrated tumors and altered by SN or S+SN treatment are highlighted. Select TCR/CD3 pathway genes include (G) signaling molecules and targeted transcription factors; (H) costimulatory receptors and negative regulatory genes; and (I) cytokine/chemokine genes. (J and K) Freshly isolated CD4+ TIL from patients (TIL062 and TIL064; Supplemental Table 1C) and CD4+ memory T cells from D-PB were immediately extracted or rested for 24 hours. Specific gene changes in the two rested TIL were compared with P1–P10 TIL. Expression levels for the commonly altered genes are shown in J, with specific TCR/CD3 pathway and cytokine/chemokine genes highlighted in K.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts